Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.
Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.
复制标题
降低同种异体干细胞移植治疗唐氏综合症 AML 的强度调节。
DOI：
10.1002/pbc.24883
复制
发表时间：
2014
影响因子：
3.2
通讯作者：
Kudo K.
中科院分区：
文献类型：
--
作者：
Muramatsu H;Sakaguchi H;Taga T;Tabuchi K;Adachi S;Inoue M;Kitoh T;Suminoe A;Yabe H;Azuma E;Shioda Y;Ogawa A;Kinoshita A;Kigasawa H;Osugi Y;Koike K;Kawa K;Kato K;Atsuta Y;Kudo K.
由于担心移植相关的毒性反应，异基因造血干细胞移植(HSCT)尚未广泛应用于急性髓系白血病(AML)和唐氏综合征(DS)患者。对15例AML和DS患者行异基因HSCT的结果进行了回顾性分析。低强度预适应组5例(完全缓解组4例，非缓解组1例)的存活率明显高于常规预适应组10例(完全缓解组4例，非缓解组6例)(3年生存率(95%可信区间)：80.0%(20.4~96.9%)vs 10.0%(0.6%~35.8%)，P= 0.039)。儿科血癌杂志2014；61：925-927。©2013 Wiley期刊，Inc.
Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation‐related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non‐CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non‐CR) (3‐year EFS (95% confidence interval): 80.0% (20.4–96.9%) vs. 10.0% (0.6%–35.8%),P= 0.039). Pediatr Blood Cancer 2014;61:925–927. © 2013 Wiley Periodicals, Inc.